Driving Impairment Associated with Psychotropic Medication

Psychotropic medications encompass a broad spectrum of agents acting on the central nervous system to treat conditions such as anxiety, insomnia, depression and psychotic disorders. By modulating neurotransmitter systems, these drugs often induce sedation, slowed reaction times, impaired attention and motor incoordination. Such effects compromise the cognitive and psychomotor functions essential for safe vehicle operation, notably reducing lane-keeping stability, delaying decision making and diminishing hazard perception. Experimental assessments—ranging from on-the-road driving tests to simulator paradigms and psychometric batteries—have established impairment thresholds commonly benchmarked against legal blood alcohol concentrations. Epidemiological investigations further associate both therapeutic and non-medical use of benzodiazepines, z-hypnotics, antidepressants and antipsychotics with elevated risks of traffic collisions. Given the global prevalence of psychotropic prescribing and the mobility requirements of affected populations, this issue carries considerable public health and regulatory significance. Mitigation strategies include the development of non-sedating alternatives, refinement of warning labels and targeted education for clinicians and patients regarding timing of dosing relative to driving tasks. Advances in real-time neurophysiological monitoring and sophisticated lane-tracking metrics also hold promise for more sensitive detection of impairment. A coordinated effort among regulators, healthcare professionals and researchers is essential to balance therapeutic benefits with road safety imperatives.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Driving Impairment Associated with Psychotropic Medication publication trend

The graph below shows the total number of articles in driving impairment associated with psychotropic medication across all publications each year (not limited to Nature Index journals).

Technical terms

Standard deviation of lateral position (SDLP): A quantitative metric of weaving that reflects the consistency of a vehicle’s lateral movements on the road.

Blood alcohol concentration (BAC): The proportion of alcohol in the bloodstream, expressed as a percentage, used to assess levels of intoxication.

Benzodiazepines: A class of sedative–hypnotic agents acting on the central nervous system, commonly prescribed for anxiety and insomnia.

References

1. Acute administration of alprazolam, alcohol and their combination on cognitive performance and mood: A randomised, double-blind, placebo-controlled study. Journal of Psychopharmacology (2023).
2. A pooled analysis of on-the-road highway driving studies in actual traffic measuring standard deviation of lateral position (i.e., “weaving”) while driving at a blood alcohol concentration of 0.5 g/L. Psychopharmacology (2017).
3. Use of psychotropic medication and risk of road traffic crashes: a registry-based case–control study in Denmark, 1996–2018. Psychopharmacology (2022).
4. Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers. Journal of Psychiatric Research (2020).
5. Behavioral and Neurophysiological Signatures of Benzodiazepine-Related Driving Impairments. Frontiers in Psychology (2015).
6. Validating lane drifts as a predictive measure of drug or sleepiness induced driving impairment. Psychopharmacology (2020).